Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
OSMITROL 20% IN WATER IN PLASTIC CONTAINER vs MANNITOL 10% W/ DEXTROSE 5% IN DISTILLED WATER
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Osmotic diuretic that increases plasma osmolality, drawing water from intracellular spaces into extracellular fluid and increasing renal tubular osmotic pressure, thereby inhibiting water reabsorption and promoting diuresis.
Mannitol is an osmotic diuretic that increases plasma osmolality, drawing water from intracellular spaces into the extracellular fluid and bloodstream, thereby reducing cerebral edema and promoting diuresis. Dextrose provides a source of calories and may help prevent hypoglycemia.
Reduction of intracranial pressure and cerebral edema,Reduction of intraocular pressure when administered intravenously,Promotion of diuresis in the prevention of acute renal failure,Diagnostic aid for renal function measurement
Reduction of intracranial pressure,Reduction of intraocular pressure,Promotion of diuresis in oliguric acute renal failure (prophylaxis or treatment),Osmotic diuresis for drug overdose (e.g., salicylates, barbiturates),Irrigation solution during transurethral prostatic resection
0.25-1 g/kg intravenously over 30-60 minutes, repeated every 6-12 hours if needed.
Adult: 50-100 g (500-1000 m L of 10% solution) intravenously over 1-2 hours, repeated as needed every 6-12 hours. Individualize based on urine output and serum osmolality.
Terminal elimination half-life is 0.25–1.5 hours in normal renal function; prolonged to 4–6 hours with anuria or oliguria. Clinically, osmotic diuresis lasts as long as urine output sustains concentration.
Terminal elimination half-life of mannitol is approximately 1.5-2 hours in patients with normal renal function. Clinically, duration of osmotic diuresis parallels half-life; in renal impairment, half-life may extend to 24-36 hours, increasing risk of fluid overload and electrolyte disturbances.
Not significantly metabolized; excreted unchanged by the kidneys via glomerular filtration.
Mannitol is not significantly metabolized; it is excreted unchanged by the kidneys. Dextrose is metabolized via glycolysis to pyruvate and lactic acid, and enters the Krebs cycle for energy production.
Primarily renal (90-100% unchanged) via glomerular filtration; <3% metabolized in liver; minimal biliary/fecal excretion.
Primarily renal excretion: Mannitol is filtered by glomeruli and not reabsorbed, excreted unchanged in urine (approximately 80-90% within 24 hours). Biliary/fecal elimination is negligible (<5%). Dextrose is metabolized to CO2 and water; any excess is excreted renally as glucose if threshold exceeded.
Approximately 0%; no significant protein binding.
Mannitol is not significantly bound to plasma proteins (<1%). Dextrose is not protein bound.
0.3–0.6 L/kg; distributes primarily in extracellular fluid, limited intracellular penetration. Higher Vd in edema states.
Approximately 0.5-0.6 L/kg. Mannitol distributes primarily in extracellular fluid (ECF); it does not enter cells significantly. Clinically, this low Vd indicates confinement to ECF, important for osmotic effects.
Intravenous: 100% (only route of administration); oral bioavailability is negligible due to poor absorption and osmotic diarrhea.
Intravenous: 100% bioavailability. Oral bioavailability is negligible (<10%) as mannitol is poorly absorbed and acts as an osmotic laxative; Dextrose is well absorbed orally (100%) but not relevant for this IV formulation.
Contraindicated in anuria; for oliguria, monitor urine output closely; no specific GFR-based dose adjustment established, but use with caution in renal impairment.
Contraindicated in anuria or severe renal impairment (GFR < 20 m L/min). For GFR 20-50 m L/min, use with caution and monitor serum osmolality; reduce dose or extend interval. No specific dose reduction formula established.
No specific Child-Pugh based adjustment; use with caution in hepatic failure.
No specific adjustments required for hepatic impairment. Monitor fluid and electrolyte balance due to potential volume expansion.
0.25-1 g/kg intravenously over 30-60 minutes, repeat every 4-6 hours as needed; maximum 2 g/kg/day.
0.25-1 g/kg (2.5-10 m L/kg of 10% solution) intravenously over 30-60 minutes, repeated as needed. Max dose 2 g/kg/day. Adjust based on response and serum osmolality.
Start at lower end of dosing range (0.25 g/kg) due to decreased renal function; monitor electrolytes and renal function closely.
Use lower initial doses and monitor renal function and electrolytes closely due to age-related decline in renal function and higher risk of volume overload. Start at 25-50 g (250-500 m L of 10% solution) and titrate.
May cause osmotic nephrosis and acute renal failure, especially with doses >200 g or in patients with pre-existing renal disease.
None.
Monitor serum electrolytes, osmolarity, and renal function,Avoid extravasation as it may cause tissue necrosis,Use with caution in patients with cardiac or pulmonary congestion,May precipitate heart failure due to volume expansion
Monitor serum electrolytes, osmolality, and renal function during therapy,May cause fluid and electrolyte imbalances, including hyponatremia or hypernatremia,Administer cautiously in patients with renal impairment, heart failure, or pulmonary edema,Use with caution in conditions where increased intravascular volume may be harmful,Do not administer if solution contains particulate matter or is discolored
Anuria due to severe renal disease,Severe pulmonary congestion or edema,Active intracranial bleeding (except during craniotomy),Severe dehydration,Hypersensitivity to mannitol
Anuria due to severe renal disease,Severe dehydration,Intracranial hemorrhage (unless during craniotomy),Active intracranial bleeding except during craniotomy,Hypersensitivity to mannitol or dextrose,Congestive heart failure,Pulmonary edema
No specific food interactions. Maintain adequate hydration as directed. Patients with electrolyte imbalances may require dietary modifications (e.g., sodium or potassium adjustments) based on serum levels. Avoid excessive fluid intake unless instructed, as it may counteract the osmotic effect.
No clinically relevant food interactions.
Pregnancy Category C. Animal reproduction studies have not been conducted. Osmotic diuretics may cause maternal dehydration and electrolyte imbalances. Inadequate human data across all trimesters; potential fetal harm if maternal hypovolemia or severe electrolyte disturbances occur. Use only if clearly needed.
No evidence of teratogenicity in animal studies; limited human data. Mannitol crosses the placenta; risk of fetal electrolyte disturbances and dehydration with maternal overdose. First trimester: theoretical risk only, no reported malformations. Second/third trimesters: monitor for maternal hyperosmolality and fluid shifts which may affect fetal hydration status.
Excretion in human milk unknown. Avoid breastfeeding during administration due to potential for adverse effects in infant (e.g., electrolyte imbalance, dehydration). M/P ratio is not available.
Not known if mannitol or dextrose are excreted in breast milk. Consider risk of osmotic diarrhea in neonate if present in milk. M/P ratio not established.
No established dose adjustments specific to pregnancy. Monitor for increased plasma volume and reduced serum osmolality in pregnancy; adjust dose to avoid overcorrection or depletion. Titrate based on clinical response and laboratory values.
No specific dose adjustment recommended; monitor maternal fluid status closely as pregnancy increases risk of pulmonary edema; adjust rate based on urine output and osmolality.
Osmotrol 20% (mannitol) is a hyperosmotic agent used to reduce intracranial pressure (ICP) and cerebral edema. Administer via IV infusion using an in-line filter (pore size ≤5 microns) to prevent mannitol crystals from entering the circulation. Monitor serum osmolality closely; target <320 m Osm/L to avoid acute kidney injury. Rapid administration can cause transient hypervolemia, which may precipitate heart failure in susceptible patients. Onset of action typically within 15–30 minutes for ICP reduction. Extravasation risk: mannitol causes venous irritation; stop infusion immediately if pain or swelling occurs.
Monitor serum sodium and osmolality closely; risk of hypernatremia and acute kidney injury. Use an in-line filter to prevent crystallization. Administer by slow IV infusion to avoid fluid overload. Contraindicated in anuria and severe pulmonary edema.
This medication is given through a vein to reduce swelling in the brain or to promote urine output.,Report any burning, pain, or redness at the IV site immediately.,You may experience increased thirst or a dry mouth during treatment.,Kidney function and blood levels will be monitored regularly while receiving this medication.,If you have a history of heart failure or kidney problems, inform your healthcare provider.,Do not drive or operate machinery if you feel dizzy or faint.,Tell your doctor about all other medications you are taking, especially diuretics or medications that affect kidney function.
Report any signs of fluid overload like shortness of breath or swelling.,This medicine may cause increased urination and thirst.,Do not take this medication by mouth; it is for intravenous use only.,Inform your healthcare provider if you have kidney problems or heart failure.
No interactions on record
"Concomitant use of clonidine and mannitol may potentiate the hypotensive effect of clonidine, leading to an increased risk of severe hypotension, syncope, and orthostatic hypotension. Mannitol, an osmotic diuretic, can cause volume depletion and electrolyte disturbances, which may exacerbate clonidine's sympatholytic effects on blood pressure regulation. This interaction is particularly concerning in patients with pre-existing cardiovascular conditions or those receiving other antihypertensive agents."
"Mannitol, an osmotic diuretic, induces intravascular volume expansion followed by diuresis, which can cause electrolyte disturbances, particularly hypokalemia and hypomagnesemia. Nifedipine, a calcium channel blocker, can further lower blood pressure through vasodilation. The combination may enhance the hypotensive effect and increase the risk of arrhythmias due to electrolyte imbalances."
"Coadministration of candesartan cilexetil, an angiotensin II receptor blocker (ARB), with mannitol, an osmotic diuretic, can result in an additive hypotensive effect due to overlapping mechanisms that reduce blood pressure. Mannitol increases renal water excretion, decreasing plasma volume and preload, while candesartan inhibits angiotensin II-mediated vasoconstriction and aldosterone secretion, leading to vasodilation and reduced afterload. This combined effect may predispose patients to symptomatic hypotension, especially in those with volume depletion or renal impairment."
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about OSMITROL 20% IN WATER IN PLASTIC CONTAINER vs MANNITOL 10% W/ DEXTROSE 5% IN DISTILLED WATER, answered by our medical review team.
OSMITROL 20% IN WATER IN PLASTIC CONTAINER is a Osmotic Diuretic that works by Osmotic diuretic that increases plasma osmolality, drawing water from intracellular spaces into extracellular fluid and increasing renal tubular osmotic pressure, thereby inhibiting water reabsorption and promoting diuresis.. MANNITOL 10% W/ DEXTROSE 5% IN DISTILLED WATER is a Osmotic Diuretic that works by Mannitol is an osmotic diuretic that increases plasma osmolality, drawing water from intracellular spaces into the extracellular fluid and bloodstream, thereby reducing cerebral edema and promoting diuresis. Dextrose provides a source of calories and may help prevent hypoglycemia.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between OSMITROL 20% IN WATER IN PLASTIC CONTAINER and MANNITOL 10% W/ DEXTROSE 5% IN DISTILLED WATER depend on the specific clinical indication. These are both Osmotic Diuretic agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of OSMITROL 20% IN WATER IN PLASTIC CONTAINER is: 0.25-1 g/kg intravenously over 30-60 minutes, repeated every 6-12 hours if needed.. The standard adult dose of MANNITOL 10% W/ DEXTROSE 5% IN DISTILLED WATER is: Adult: 50-100 g (500-1000 m L of 10% solution) intravenously over 1-2 hours, repeated as needed every 6-12 hours. Individualize based on urine output and serum osmolality.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between OSMITROL 20% IN WATER IN PLASTIC CONTAINER and MANNITOL 10% W/ DEXTROSE 5% IN DISTILLED WATER in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. OSMITROL 20% IN WATER IN PLASTIC CONTAINER is classified as Category C. Pregnancy Category C. Animal reproduction studies have not been conducted. Osmotic diuretics may cause maternal dehydration and electrolyte imbalances. Inadequate human data across. MANNITOL 10% W/ DEXTROSE 5% IN DISTILLED WATER is classified as Category A/B. No evidence of teratogenicity in animal studies; limited human data. Mannitol crosses the placenta; risk of fetal electrolyte disturbances and dehydration with maternal overdose. F. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.